AIM ImmunoTech (AIM) Scheduled to Post Earnings on Tuesday

AIM ImmunoTech (NYSE:AIMGet Free Report) is scheduled to post its quarterly earnings results on Tuesday, April 2nd.

AIM ImmunoTech Price Performance

AIM ImmunoTech stock opened at $0.47 on Monday. AIM ImmunoTech has a 12 month low of $0.32 and a 12 month high of $0.75. The company has a market cap of $23.00 million, a price-to-earnings ratio of -1.10 and a beta of -0.13. The stock’s 50-day moving average is $0.41 and its 200-day moving average is $0.45.

Insider Buying and Selling at AIM ImmunoTech

In other AIM ImmunoTech news, CEO Thomas K. Equels acquired 75,758 shares of the stock in a transaction on Friday, March 15th. The stock was purchased at an average price of $0.33 per share, for a total transaction of $25,000.14. Following the purchase, the chief executive officer now directly owns 716,455 shares in the company, valued at $236,430.15. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Stewart Appelrouth purchased 90,910 shares of the stock in a transaction dated Friday, March 15th. The stock was acquired at an average cost of $0.33 per share, for a total transaction of $30,000.30. Following the acquisition, the director now owns 239,765 shares of the company’s stock, valued at $79,122.45. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, CEO Thomas K. Equels purchased 75,758 shares of the stock in a transaction dated Friday, March 15th. The stock was purchased at an average price of $0.33 per share, with a total value of $25,000.14. Following the completion of the acquisition, the chief executive officer now directly owns 716,455 shares in the company, valued at approximately $236,430.15. The disclosure for this purchase can be found here. Insiders acquired a total of 243,009 shares of company stock worth $82,501 in the last 90 days. 0.02% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On AIM ImmunoTech

A number of institutional investors have recently made changes to their positions in AIM. DRW Securities LLC bought a new stake in shares of AIM ImmunoTech in the 2nd quarter valued at approximately $25,000. Cambridge Investment Research Advisors Inc. bought a new stake in shares of AIM ImmunoTech in the 1st quarter valued at approximately $49,000. Virtu Financial LLC increased its holdings in shares of AIM ImmunoTech by 34.9% in the 1st quarter. Virtu Financial LLC now owns 50,805 shares of the company’s stock valued at $54,000 after acquiring an additional 13,148 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of AIM ImmunoTech by 23.2% in the 1st quarter. Renaissance Technologies LLC now owns 168,708 shares of the company’s stock valued at $73,000 after acquiring an additional 31,800 shares during the last quarter. Finally, State Street Corp boosted its position in AIM ImmunoTech by 7.9% during the 1st quarter. State Street Corp now owns 173,103 shares of the company’s stock valued at $183,000 after purchasing an additional 12,690 shares during the period. 12.02% of the stock is currently owned by institutional investors.

AIM ImmunoTech Company Profile

(Get Free Report)

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).

See Also

Earnings History for AIM ImmunoTech (NYSE:AIM)

Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.